NPR this week reported that the federal government may soon ease restrictions on some peptide treatments — a development with potentially significant implications for patient access, pharmacy compounding, and the still-thriving gray market.
APC CEO Scott Brunner is quoted in the story, underscoring the need for a more rational policy approach that distinguishes legitimate, patient-focused care from unauthorized and unsafe activity.